315 related articles for article (PubMed ID: 24037843)
1. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
Lu D; Zhu Z
Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
[TBL] [Abstract][Full Text] [Related]
2. Construction and production of an IgG-like tetravalent bispecific antibody for enhanced therapeutic efficacy.
Lu D; Zhu Z
Methods Mol Biol; 2009; 525():377-404, xiv. PubMed ID: 19252849
[TBL] [Abstract][Full Text] [Related]
3. Recombinant approaches to IgG-like bispecific antibodies.
Marvin JS; Zhu Z
Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
[TBL] [Abstract][Full Text] [Related]
4. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
[TBL] [Abstract][Full Text] [Related]
5. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
8. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.
Golay J; Choblet S; Iwaszkiewicz J; Cérutti P; Ozil A; Loisel S; Pugnière M; Ubiali G; Zoete V; Michielin O; Berthou C; Kadouche J; Mach JP; Duonor-Cérutti M
J Immunol; 2016 Apr; 196(7):3199-211. PubMed ID: 26921308
[TBL] [Abstract][Full Text] [Related]
9. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
10. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
11. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
[TBL] [Abstract][Full Text] [Related]
12. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
13. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
15. Production of stabilized scFv antibody fragments in the E. coli bacterial cytoplasm.
Vaks L; Benhar I
Methods Mol Biol; 2014; 1060():171-84. PubMed ID: 24037842
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
17. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
Lu D; Jimenez X; Zhang H; Bohlen P; Witte L; Zhu Z
J Immunol Methods; 2002 Sep; 267(2):213-26. PubMed ID: 12165442
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.
Mabry R; Snavely M
IDrugs; 2010 Aug; 13(8):543-9. PubMed ID: 20721825
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification and characterization of a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen in Pichia pastoris.
Wang DD; Su MM; Sun Y; Huang SL; Wang J; Yan WQ
Protein Expr Purif; 2012 Nov; 86(1):75-81. PubMed ID: 22982755
[TBL] [Abstract][Full Text] [Related]
20. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
